Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and theoretical models without systematic review methodology or new human clinical data.
PubMed 31158953 · doi:10.5009/gnl18490
What was done
The authors conducted a narrative review synthesizing preclinical evidence on the stable gastric pentadecapeptide BPC 157, framing its biological actions within Robert's concept of stomach cytoprotection/organoprotection and Selye's stress coping response. The review evaluated its mechanistic effects across mucosal integrity, wound healing, vascular responses, and cachexia.
What was found
The abstract reports no quantitative values or statistical metrics. It qualitatively reports that BPC 157 protects gastric and extra-gastric epithelia (skin, liver, pancreas, heart, brain) against noxious agents, alcohol, and nonsteroidal anti-inflammatory drugs. It also describes endothelial protection, thrombosis reduction, vessel recruitment to bypass occlusions during ischemic/reperfusion injury, and attenuation of cancer cachexia and pro-inflammatory cytokines (IL-6, TNF-alpha) via FoxO3a, p-AKT, p-mTOR, and p-GSK-3beta pathways.
Why it matters
The paper synthesizes the theoretical and preclinical framework for BPC 157 as a broad-spectrum organoprotective agent for mucosal, vascular, and inflammatory tissue repair.
Limits
This is a narrative review with no systematic search methodology or risk-of-bias assessment. All described findings stem from bench and animal disease models, with no human clinical trial data, sample sizes, or quantitative outcome measures reported in the abstract.
Cited by
- supports In mouse studies, administration of BPC-157 demonstrated protection deeper in the gastrointestinal tract against an offending agent introduced into the gut.